Hollow mesoporous silica nanoparticles as nanocarriers employed in cancer therapy: A review
- PDF / 1,935,239 Bytes
- 14 Pages / 595.276 x 785.197 pts Page_size
- 22 Downloads / 208 Views
REVIEW ARTICLE
Hollow mesoporous silica nanoparticles as nanocarriers employed in cancer therapy: A review Yimin ZHOU, Qingni XU, Chaohua LI, Yuqi CHEN, Yueli ZHANG, and Bo LU (✉) School of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan 430070, China
© Higher Education Press 2020
ABSTRACT: Hollow mesoporous silica nanoparticles (HMSNs) have become an attractive drug carrier because of their unique characteristics including stable physicochemical properties, large specific surface area and facile functionalization, especially made into intelligent drug delivery systems (DDSs) for cancer therapy. HMSNs are employed to transport traditional anti-tumor drugs, which can solve the problems of drugs with instability, poor solubility and lack of recognition, etc., while significantly improving the anti-tumor effect. And an unexpected good result will be obtained by combining functional molecules and metal species with HMSNs for cancer diagnosis and treatment. Actually, HMSNs-based DDSs have developed relatively mature in recent years. This review briefly describes how to successfully prepare an ordinary HMSNsbased DDS, as well as its degradation, different stimuli-responses, targets and combination therapy. These versatile intelligent nanoparticles show great potential in clinical aspects. KEYWORDS: hollow mesoporous silica nanoparticles; intelligent drug delivery system; stimuli response; targeting drug delivery; combination therapy
Contents 1 Introduction 2 HMSNs as nanocarriers 2.1 HMSNs 2.2 Degradable HMSNs 3 Intelligent HMSNs-based DDSs 3.1 Endogenous stimuli-responsive HMSNs-based DDSs 3.2 Exogenous stimuli-responsive HMSNs-based DDSs 3.3 HMSNs-based targeted DDSs Received August 20, 2020; accepted September 8, 2020 E-mail: [email protected]
3.4 HMSNs-based DDSs for combination therapy 4 Conclusions Acknowledgement References
1
Introduction
Recently, nanotechnology has made great progress in biomedicine for health prevention, detection and diagnosis, and drug treatment. Especially in the field of drug treatment, because specific nanomaterials have excellent characteristics with good biocompatibility, biodegradability, drug sustained release and targeted delivery, which allow them to be made into drug carriers for transporting cargoes [1]. Distinguished drug carriers also have the
2
Front. Mater. Sci.
following features of large specific surface area, high loading capacity and easy functionalization, whose structure size distributes in the range of a few to several hundred nanometers [2]. At present, the research of nano-drug carriers mainly focuses on organic, inorganic, biodegradable nanocarrier. Remarkably, the nano-drug carriers are widely applied in anti-tumor research and treatment, such as protein nanoparticles, liposomes and polymer micelles approved by the Food and Drug Administration (FDA) as clinical anti-tumor commercialized carriers [3]. However, because the low drug loading and the inherent instability of organic carriers limit their application in drug deliv
Data Loading...
